169 related articles for article (PubMed ID: 12421042)
1. Invasive aspergillosis caused by Aspergillus terreus in a non-immunosuppressed patient.
Verghese S; Arjundas D; Shakoor TP; Padmaja P; Elizabeth SJ; Maria CF
J Assoc Physicians India; 2002 Aug; 50():1086-8. PubMed ID: 12421042
[No Abstract] [Full Text] [Related]
2. First case of breakthrough pulmonary Aspergillus niveus infection in a patient after allogeneic hematopoietic stem cell transplantation.
Auberger J; Lass-Flörl C; Clausen J; Bellmann R; Buzina W; Gastl G; Nachbaur D
Diagn Microbiol Infect Dis; 2008 Nov; 62(3):336-9. PubMed ID: 18687556
[TBL] [Abstract][Full Text] [Related]
3. Experimental pulmonary aspergillosis due to Aspergillus terreus: pathogenesis and treatment of an emerging fungal pathogen resistant to amphotericin B.
Walsh TJ; Petraitis V; Petraitiene R; Field-Ridley A; Sutton D; Ghannoum M; Sein T; Schaufele R; Peter J; Bacher J; Casler H; Armstrong D; Espinel-Ingroff A; Rinaldi MG; Lyman CA
J Infect Dis; 2003 Jul; 188(2):305-19. PubMed ID: 12854088
[TBL] [Abstract][Full Text] [Related]
4. Aspergillus susceptibility testing in patients with cancer and invasive aspergillosis: difficulties in establishing correlation between in vitro susceptibility data and the outcome of initial amphotericin B therapy.
Lionakis MS; Lewis RE; Chamilos G; Kontoyiannis DP
Pharmacotherapy; 2005 Sep; 25(9):1174-80. PubMed ID: 16164392
[TBL] [Abstract][Full Text] [Related]
5. Activity of micafungin (FK463) against an itraconazole-resistant strain of Aspergillus fumigatus and a strain of Aspergillus terreus demonstrating in vivo resistance to amphotericin B.
Warn PA; Morrissey G; Morrissey J; Denning DW
J Antimicrob Chemother; 2003 Apr; 51(4):913-9. PubMed ID: 12654746
[TBL] [Abstract][Full Text] [Related]
6. Endogenous Aspergillus endophthalmitis in a healthy individual.
Mamandhar A; Bajracharya L
Nepal J Ophthalmol; 2012; 4(1):179-83. PubMed ID: 22344019
[TBL] [Abstract][Full Text] [Related]
7. Infections due to Aspergillus terreus: a multicenter retrospective analysis of 83 cases.
Steinbach WJ; Benjamin DK; Kontoyiannis DP; Perfect JR; Lutsar I; Marr KA; Lionakis MS; Torres HA; Jafri H; Walsh TJ
Clin Infect Dis; 2004 Jul; 39(2):192-8. PubMed ID: 15307028
[TBL] [Abstract][Full Text] [Related]
8. Treatment failure in invasive aspergillosis: susceptibility of deep tissue isolates following treatment with amphotericin B.
Paterson PJ; Seaton S; Prentice HG; Kibbler CC
J Antimicrob Chemother; 2003 Nov; 52(5):873-6. PubMed ID: 14519673
[TBL] [Abstract][Full Text] [Related]
9. Successful treatment of invasive Aspergillus rhinosinusitis in a child with acute myeloid leukemia.
Jaing TH; Yang CP; Hung IJ; Chiu CH; Hsueh C
J Otolaryngol; 2000 Aug; 29(4):257-9. PubMed ID: 11003082
[No Abstract] [Full Text] [Related]
10. [Invasive aspergillosis in immunocompromised patients].
Kliasova GA; Petrova NA; Galstian GM; Gotman LN; Vishnevskaia ES; Sysoeva EP; Khoroshko ND; Mikhaĭlova EA; Parovichnikova EN; Isaev VG
Ter Arkh; 2003; 75(7):63-8. PubMed ID: 12934484
[TBL] [Abstract][Full Text] [Related]
11. Disseminated invasive aspergillosis in an apparently immunocompetent host.
Raja NS; Singh NN
J Microbiol Immunol Infect; 2006 Feb; 39(1):73-7. PubMed ID: 16440127
[TBL] [Abstract][Full Text] [Related]
12. Primary cutaneous aspergillosis--an emerging infection among immunocompromised patients.
Walsh TJ
Clin Infect Dis; 1998 Sep; 27(3):453-7. PubMed ID: 9770139
[No Abstract] [Full Text] [Related]
13. Poor efficacy of amphotericin B-based therapy in CNS aspergillosis.
Schwartz S; Ruhnke M; Ribaud P; Reed E; Troke P; Thiel E
Mycoses; 2007 May; 50(3):196-200. PubMed ID: 17472616
[TBL] [Abstract][Full Text] [Related]
14. Antifungal therapy of murine Aspergillus terreus infection.
Graybill JR; Hernandez S; Bocanegra R; Najvar LK
Antimicrob Agents Chemother; 2004 Oct; 48(10):3715-9. PubMed ID: 15388425
[TBL] [Abstract][Full Text] [Related]
15. Antifungal resistance in Aspergillus terreus: A current scenario.
Vahedi Shahandashti R; Lass-Flörl C
Fungal Genet Biol; 2019 Oct; 131():103247. PubMed ID: 31247322
[TBL] [Abstract][Full Text] [Related]
16. Invasive aspergillosis caused by Aspergillus terreus: an emerging opportunistic infection with poor outcome independent of azole therapy.
Hachem R; Gomes MZ; El Helou G; El Zakhem A; Kassis C; Ramos E; Jiang Y; Chaftari AM; Raad II
J Antimicrob Chemother; 2014 Nov; 69(11):3148-55. PubMed ID: 25006241
[TBL] [Abstract][Full Text] [Related]
17. Invasive pulmonary aspergillosis due to Aspergillus terreus: 12-year experience and review of the literature.
Iwen PC; Rupp ME; Langnas AN; Reed EC; Hinrichs SH
Clin Infect Dis; 1998 May; 26(5):1092-7. PubMed ID: 9597234
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of SCH56592 in a rabbit model of invasive aspergillosis.
Kirkpatrick WR; McAtee RK; Fothergill AW; Loebenberg D; Rinaldi MG; Patterson TF
Antimicrob Agents Chemother; 2000 Mar; 44(3):780-2. PubMed ID: 10681359
[TBL] [Abstract][Full Text] [Related]
19. Topical voriconazole solution for cutaneous aspergillosis in a pediatric patient after bone marrow transplant.
Klein KC; Blackwood RA
Pediatrics; 2006 Aug; 118(2):e506-8. PubMed ID: 16816005
[TBL] [Abstract][Full Text] [Related]
20. Primary cutaneous aspergillosis in a patient with cutaneous T-cell lymphoma.
Yuanjie Z; Jingxia D; Hai W; Jianghan C; Julin G
Mycoses; 2009 Sep; 52(5):462-4. PubMed ID: 18983429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
